Background:
- The experimental drug NHS-IL12 may help the immune system become more active and kill
cancer cells that have not responded to standard treatments. NHS-IL12 has been designed to
cause less severe side effects than other anticancer drugs, and may be more effective. More
research is needed to test NHS-IL12 in people who have solid tumors that have not responded
to treatment.
Objectives:
- To test the safety and effectiveness of NHS-IL12 as a treatment for solid tumors which have
not responded to standard treatments.
Eligibility:
- Individuals at least 18 years of age with solid tumors that have not responded to standard
treatments.
Design:
- Participants will be screened with a medical history, physical exam, blood and urine
tests, and imaging studies.
- Participants will receive NHS-IL12 injection every 4 weeks, and will stay in the
hospital for at least one day to be monitored with frequent blood tests.
- Participants will have periodic blood samples taken before treatment and during the
first week after treatment for the first two cycles. They will then have blood samples
taken before treatment for the rest of the cycles.